Phase 2 Results of Perifosine in the Treatment of Patients with
Relapsed/Refractory Waldenstrom's Macroglobulinemia to be presented
Tomorrow, Tuesday, June 3rd at 12:00pm in Room E450a
NEW YORK, June 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that abstracts related to KRX-0401 (Perifosine) have been selected for both poster presentation and publication during the American Society of Clinical Oncology Meeting currently taking place in Chicago, Illinois (May 31 - June 3, 2008).
Copies of these abstracts, which highlight the observed clinical and preclinical activity of KRX-0401 as a single agent and in combination with novel agents are currently available and can be viewed on-line through the ASCO website: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts
The following abstract will be available for viewing during the poster session taking place tomorrow, Tuesday, June 3, 2008, from 8:00am-12:00pm:
Abstract 8546: A Phase 2 trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia
Investigators: Irene M. Ghobrial, X. Leleu, N. Rubin, R. Leduc, S. Chuma, M. Nelson, P. G. Richardson, S. P. Treon, K. C. Anderson
Following the poster session, lead investigator, Dr. Irene Ghobrial, will be presenting the abstract during the Lymphoma and Plasma Cell Disorders Poster Discussion Forum, scheduled to take place at 12:00pm in Room E450a.
Additionally, the following abstracts have been accepted for publication only:
Abstract 16024: Phase 1 multicenter trial of perifosine in
|SOURCE Keryx Biopharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved